DB05741ExperimentalSmall molecule
AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.
- Primary indication
- Investigated for use/treatment in leukemia (lymphoid).Curator reviewed
- Code names
- AGS-005
Which companies are running trials of AGS-005, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account